2016
DOI: 10.17996/anc.02.01.152
|View full text |Cite
|
Sign up to set email alerts
|

<sup>123</sup>I-Meta-Iodobenzylguanidine Imaging

Abstract: Abstract123 I-meta-iodobenzylguanidine (MIBG) is a potent prognostic marker of chronic heart failure (CHF). However, inter-institutional variations due to methodological variations required minimization before 123 I-MIBG findings could be universally applied to the diagnosis, treatment and prognosis of CHF. Therefore, protocols including data acquisition, setting regions of interest for calculating heart-to-mediastinum ratios (HMR) and crosscalibration of HMR among institutions required standardization. A cros… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Year Published

2016
2016
2017
2017

Publication Types

Select...
3

Relationship

1
2

Authors

Journals

citations
Cited by 3 publications
references
References 27 publications
0
0
0
Order By: Relevance